HALO® is the most technologically advanced assay platform available for multiple lymph-hematopoietic stem and progenitor cell populations. It replaces the CFU assay by being:



  • Instrument-based
  • Non-subjective
  • Standardized and validated
  • Incorporates SEC™ Technology and, therefore, methylcellulose-free
  • Allows high-throughput capability in 96- or 384-well plates
  • Has built-in proficiency testing
  • More rapid (results in 6 days or less), reliable and reproducible than any CFU assay
  • Available for multiple species and different applications
  • Used by biopharmaceutical companies worldwide



To learn more about HALO® and our other instrument-based hematopoietic assays, please visit our website or contact us directly by calling 719-264-6251 or e-mailing info@preferred-cell-systems.com.


 
Facebook  X  Instagram  LinkedIn